Innovating.works Conecta tu I+D

Showing 1 to 20 of 176 results

SciLifeLab PULSE: SciLifeLab Programme for fUture Leaders in life SciencE SciLifeLab PULSE is a MSCA-COFUND postdoctoral programme of excellence in Life Sciences coordinated by the Swedish research infrastructure S...
2024-09-16 - 2030-08-31 | Financiado

ERDERA: EUROPEAN RARE DISEASES RESEARCH ALLIANCE ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-07 The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare...
2024-08-20 - 2031-08-31 | Financiado

NATPRIME: Effective Delivery of Nucleic Acid Therapeutics via Designed Nanocarriers ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 Delivery of Nucleic Acid Therapeutics to desired organs has become the current challenge of biotechnological applications. Advancements on t...
2024-07-10 - 2028-09-30 | Financiado

MC4DD: Macrocycles for Drug Discovery Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe. New d...
2024-07-10 - 2028-10-31 | Financiado

MeCHaNiSM: Mechanical Characterisation of Nucleic Acids using Single Molecule Methods Nucleic acid (NAs)-based therapies have started to yield major advances in the treatment of human disease. New approaches for understanding...
2024-07-08 - 2028-09-30 | Financiado

EFFECT: A European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across... "The EFFecT Doctoral Training (DN) Network responds to the evolving landscape of RNA-based therapeutics and in particular antisense oligonuc...
2024-07-05 - 2028-12-31 | Financiado

TargetRNA: Targeting RNA with small molecules RNA molecules play key roles in biological processes and diseases. An emerging avenue to develop innovative medicines is therefore to design...
2024-06-25 - 2028-08-31 | Financiado

GRANITE: Integrated AI Diagnostics in Breast Cancer ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 In EU-27, it is estimated that >355,000 were diagnosed with breast cancer (BC) in 2020. Initiatives to reduce this burden in Europe involve...
2024-03-13 - 2026-09-01 | Financiado

LIVERAIM: A Biomarker Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Thera... ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-JU-IHI-2022-03-single-stage Liver cirrhosis and liver cancer are common and responsible for high morbidity, impaired quality of life, major costs for healthcare systems...
2023-11-27 - 2030-02-28 | Financiado

CirculH2: Hydrogenases for Large Scale Deployment of H2 as a Circular Energy Carrier in Industrial Biotechnolo... ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-CL6-2023-CIRCBIO-01 Rapid transition toward the use of renewable, energy-efficient and recyclable resource is needed in industrial biotechnology to achieve sust...
2023-11-22 - 2027-12-31 | Financiado

CURE HEARTandBRAIN: CURE HEARTandBRAIN postdoctoral COFUND programme by CNIC ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2022-COFUND-01 The CNIC (Spanish Centre for Cardiovascular Research) is a worldwide recognised research centre dedicated to cardiovascular research. CNIC’s...
2023-09-19 - 2028-12-31 | Financiado

ORGESTRA: Organoid technologies for disease modeling, drug discovery and development for rare diseases ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2022-DN-01 The vast majority of rare diseases are characterized by genetic origin, often severe in pathology and with limited or no treatment options....
2023-07-11 - 2027-12-31 | Financiado

FluoNeeD: Fluorinated Lipid Nanoparticles for Gene Delivery and Diagnostics ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 The formulation of drug nanocarriers has attracted increasing attention over the last decades. In particular, the possibility to combine the...
2023-04-28 - 2026-08-31 | Financiado

PRISMAS: PhD Research and Innovation in Synchrotron Methods and Applications in Sweden ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 The PRISMAS initiative is proposed by MAX IV, Lund Universiteit faculty, to meet a two-fold objective: (1) ensure Sweden can take the lead o...
2022-11-21 - 2027-12-31 | Financiado

ISOBIOTICS: Isotopic Labeling of Biotherapeutics ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-MSCA-2021-DN-01 Biological drugs such as peptides, proteins, oligonucleotides and analogs provide the patients with more efficacious and less toxic treatmen...
2022-07-14 - 2027-01-31 | Financiado

LiverTarget: Next generation advanced RNA inhibition therapy to treat cardiometabolic disease ASTRAZENECA AB participó en un HORIZON EUROPE: HORIZON-HLTH-2021-TOOL-06 RNA Therapeutics comprise a new rapidly expanding category of drugs including small interfering RNAs (siRNA) and messenger RNAs (mRNA) that...
2022-05-24 - 2027-04-30 | Financiado

OPTIMA: Optimal treatment for patients with solid tumours in Europe through Artificial intelligence ASTRAZENECA AB participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage OPTIMA is a multi-stakeholder-led consortium with the vision that each and every patient should have access to the most up-to-date individua...
2021-10-18 - 2026-09-30 | Financiado

FACILITATE: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical eco... ASTRAZENECA AB participó en un H2020: H2020-JTI-IMI2-2020-23-two-stage FACILITATE is a project built on a patient-centered, data-driven, technological platform where an innovative data sharing and re-use process...
2021-10-11 - 2025-12-31 | Financiado

RealHOPE: Real World Handling of Protein Drugs Exploration Evaluation and Education ASTRAZENECA AB participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage RealHOPE will create an understanding of the real-life handling of protein drugs in hospital pharmacy, clinics and in the hands of patients...
2021-07-05 - 2025-06-30 | Financiado

PERSIST-SEQ: Building a reproducible single cell experimental workflow to capture tumour cell persistence ASTRAZENECA AB participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by deve...
2021-06-28 - 2026-06-30 | Financiado